AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY [STUDIO DI FASE 2, IN APERTO, RANDOMIZZATO VOLTO A CONFRONTARE TAS-102 RISPETTO A TOPOTECAN O AMRUBICINA IN PAZIENTI CHE NECESSITANO DI CHEMIOTERAPIA DI SECONDA LINEA PER IL CARCINOMA POLMONARE A PICCOLE CELLULE REFRATTARIO O SENSIBILE ALLA CHEMIOTERAPIA DI PRIMA LINEA A BASE DI PLATINO].

Trial Profile

AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY [STUDIO DI FASE 2, IN APERTO, RANDOMIZZATO VOLTO A CONFRONTARE TAS-102 RISPETTO A TOPOTECAN O AMRUBICINA IN PAZIENTI CHE NECESSITANO DI CHEMIOTERAPIA DI SECONDA LINEA PER IL CARCINOMA POLMONARE A PICCOLE CELLULE REFRATTARIO O SENSIBILE ALLA CHEMIOTERAPIA DI PRIMA LINEA A BASE DI PLATINO].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Amrubicin; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 11 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 08 Jan 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 19 Jul 2013 Planned end date (Oct 2015) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top